It demonstrates that JNK and GSK-3β could serve as promising therapeutic targets for the management and treatment of AD (Zhou et al., 2015; Yarza et al., 2016; Yang et al., 2016; Li et al., 2023). The gene discussed is MAPK8; the disease is Alzheimer disease.